Eli Lilly receives FDA approval for its Alzheimer’s drug Kisunla

July 02, 2024 11:59 AM PDT | By Invezz

Eli Lilly receives FDA approval for its Alzheimer’s drug Kisunla — Image source: Invezz

Is Kisunla news significant for Eli Lilly stock?

Alzheimer’s is among the top five causes of deaths for Americans aged more than 65.

More importantly, the number of patients suffering from this mind-wasting disease is expected to hit 13 million in the United States by 2050, which underscores the urgent need for effective treatments like Lilly’s donanemab.

Securing FDA approval for its Alzheimer’s drug is a major breakthrough for Eli Lilly. That’s because the U.S. regulator cited insufficient data as it rejected donanemab last year. The approval faced unexpected delay in March of 2024 as well.

The Alzheimer’s news may unlock the next leg up in Eli Lilly stock that has outperformed this year on the back of strong demand for its weight-loss drug.

Many expect LLY to be the first healthcare name to hit $1.0 trillion in valuation.

Lilly to compete directly with Biogen

FDA’s full approval for Lilly’s Alzheimer’s drug arrives shortly after its advisory panel concluded the benefits of donanemab outweigh the risks.

The $870 billion behemoth will now compete directly with Biogen that secured approval for Leqembi (its Alzheimer’s drug) in summer of 2023. Donanemab is set to become the third treatment for Alzheimer’s to hit the market in the U.S.

Both Leqembi and Donanemab are monoclonal antibodies that target amyloid plaques. Neither is a definitive cure and both can have potential safety concerns including brain swelling and bleeding that can sometimes be fatal.

Three patients, for example, in the late-stage study of Eli Lilly died due to ARIA (amyloid-related imaging abnormalities). Watch here: https://www.youtube.com/embed/gO2ShFRucNM?feature=oembed

Other recent developments related to LLY

Note that Eli Lilly will market its Alzheimer’s drug as “Kisunla”. In June, former FDA commissioner Dr Scott Gottlieb said Alzheimer’s could be a very big category for LLY.

The donanemab news arrives a couple weeks after the New York listed firm announced $1.30 a share of dividend for the third quarter.

It also teamed up with OpenAI last month to tap on artificial intelligence to discover novel medicines and treat drug-resistant bacteria. Brad Lightcap – the chief operating officer of LLY said at the time:

Advanced AI has the potential to deliver innovative breakthroughs in pharma, and we’re committed to working together with industry leaders to deliver tangible benefits for patients.

The post Eli Lilly receives FDA approval for its Alzheimer's drug Kisunla appeared first on Invezz

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.